{"url_path":"/sec/biaf/8-k/2026-07-22/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1712762/0001493152-26-034183-index.html","accession_number":"0001493152-26-034183","cik":"0001712762","ticker":"BIAF","issuer_name":"bioAffinity Technologies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1712762/0001493152-26-034183-index.html","primary_entity_key":"0001712762","primary_entity_name":"bioAffinity Technologies, Inc."},"word_count":376,"has_tables":true,"body_markdown":"false\n0001712762\n\n0001712762\n\n2026-07-22\n2026-07-22\n\n0001712762\n\nBIAF:CommonStockParValue0.007PerShareMember\n\n2026-07-22\n2026-07-22\n\n0001712762\n\nBIAF:WarrantsToPurchaseCommonStockMember\n\n2026-07-22\n2026-07-22\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n8-K**\n\n \n\n**CURRENT\nREPORT**\n\n \n\nPursuant\nto Section 13 or 15(d) of the Securities Exchange Act of 1934\n\n \n\nDate\nof Report (Date of earliest event reported): **July 22, 2026**\n\n \n\n**bioAffinity\nTechnologies, Inc.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**001-41463**\n \n**46-5211056**\n\n(State\nor other jurisdiction\n\nof\nincorporation)\n\n \n\n(Commission\n\nFile\nNumber)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNumber)\n\n \n\n**3300\nNacogdoches Road, Suite 216**\n\n**San\nAntonio, Texas 78217**\n\n(Address\nof principal executive offices, including zip code)\n\n \n\n**(210)\n698-5334**\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\n \n\n(Former\nname or former address, if changed since last report)\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions (see General Instruction A.2. below):\n\n \n\n☐\nWritten\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nTitle\nof each class\n \nTrading\nSymbols\n \nName\nof each exchange on which registered\n\nCommon\nStock, par value $0.007 per share\n\n \n\n \n\n \n\nBIAF\n\n \n\n \n\nThe\nNasdaq Stock Market LLC\n\n(Nasdaq\nCapital Market)\n\n \n \n \n \n \n\nWarrants\nto purchase Common Stock\n \nBIAFW\n \n\nThe\nNasdaq Stock Market LLC\n\n(Nasdaq\nCapital Market)\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ☒\n\n \n\nIf\nan emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}